News von VION von heute:
Vion Initiates Phase 2 Trial of Triapine(R) and Gemcitabine in Pancreatic Cancer
NEW HAVEN, Conn., May 28, 2003 /PRNewswire-FirstCall via COMTEX/ -- VION
PHARMACEUTICALS, INC. (Nasdaq: VION) announced today that it had initiated a new
Phase 2 trial of Triapine(R) in combination with gemcitabine in patients with
metastatic or advanced pancreatic cancer. Enrollment of patients began at the
Sarah Cannon Cancer Center in Nashville, Tennessee under the direction of Dr.
Howard Burris.
Data from a Phase 1 trial of Triapine(R) and gemcitabine will be presented in a
poster presentation at the American Society of Clinical Oncology Annual Meeting
in June 2003. Vion recently initiated a similar Phase 2 trial of Triapine(R) and
gemcitabine in patients with non-small-cell lung cancer.
Triapine(R) is designed to be a potent inhibitor of ribonucleotide reductase, an
enzyme important for DNA synthesis. Gemcitabine is sold under the brand name
Gemzar(R) by Eli Lilly & Company.
Vion Pharmaceuticals, Inc. is a biopharmaceutical company developing novel
agents for the treatment of cancer. Vion's portfolio of agents includes:
Triapine(R), a potent inhibitor of a key step in DNA synthesis; VNP40101M, a
unique DNA alkylating agent; and TAPET(R), a modified Salmonella vector used to
deliver anticancer agents directly to tumors. For additional information on Vion
and its research and product development programs, visit the company's Internet
web site at www.vionpharm.com.
This news release contains forward-looking statements. Such statements are
subject to certain risk factors which may cause Vion's plans to differ or
results to vary from those expected, including Vion's ability to continue as a
going concern, which is dependent on securing external sources of funding to
continue its operations, the inability to access capital and funding on
favorable terms, continued operating losses and the inability to continue
operations as a result, its dependence on regulatory approval for its products,
delayed or unfavorable results of drug trials, the possibility that favorable
results of earlier clinical trials are not predictive of safety and efficacy
results in later clinical trials, the need for additional research and testing,
and a variety of other risks set forth from time to time in Vion's filings with
the Securities and Exchange Commission, including but not limited to the risks
discussed in Vion's Annual Report on Form 10-K for the year ended December 31,
2002. Except in special circumstances in which a duty to update arises under law
when prior disclosure becomes materially misleading in light of subsequent
events, Vion does not intend to update any of these forward-looking statements
to reflect events or circumstances after the date hereof or to reflect the
occurrence of unanticipated events.
Contact:
Howard B. Johnson, CFO
Vion Pharmaceuticals, Inc.,
203-498-4210
SOURCE Vion Pharmaceuticals, Inc.
Werbung
mgroen.bei.t-online.de/Er%f6ffnung%2022%20KW.jpg"
